Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium

<p>Abstract</p> <p>Background</p> <p>In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported that selenium concentratio...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Goossens Maria E, Buntinx Frank, Joniau Steven, Ackaert Koen, Ameye Filip, Billiet Ignace, Braeckman Johan, Breugelmans Alex, Darras Jochen, Dilen Kurt, Goeman Lieven, Kellen Eliane, Tombal Bertrand, Van Bruwaene Siska, Van Cleyenbreuge Ben, Van der Aa Frank, Vekemans Kris, Van Poppel Hendrik, Zeegers Maurice P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMC 2012-03-01
Seri Bilgileri:BMC Urology
Konular:
Selenium
Bladder cancer
Transitional Cell Carcinoma
Chemoprevention
Randomized clinical trial
Urology
Online Erişim:http://www.biomedcentral.com/1471-2490/12/8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller